Hansa Biopharma Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Renee Aguiar-Lucander
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | n/a |
| Management average tenure | 4.1yrs |
| Board average tenure | 4yrs |
Recent management updates
Recent updates
Idefirix Expansion And Clinical Trials Will Open New Markets
Apr 02 Expanding Idefirix in Europe and securing reimbursements may enhance revenue by increasing market penetration and adoption rates.Downgrade: Here's How Analysts See Hansa Biopharma AB (publ) (STO:HNSA) Performing In The Near Term
Feb 12
Hansa Biopharma AB (publ) (STO:HNSA) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Feb 09It's Down 26% But Hansa Biopharma AB (publ) (STO:HNSA) Could Be Riskier Than It Looks
Feb 08Hansa Biopharma AB (publ) (STO:HNSA) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable
Dec 22It's Down 30% But Hansa Biopharma AB (publ) (STO:HNSA) Could Be Riskier Than It Looks
Nov 07Hansa Biopharma AB (publ) (STO:HNSA) Just Released Its Third-Quarter Earnings: Here's What Analysts Think
Oct 20Investors Appear Satisfied With Hansa Biopharma AB (publ)'s (STO:HNSA) Prospects As Shares Rocket 28%
Aug 24Hansa Biopharma AB (publ) (STO:HNSA) Analysts Just Slashed This Year's Revenue Estimates By 11%
Jul 23Hansa Biopharma AB (publ) (STO:HNSA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Jul 21Shareholders May Be Wary Of Increasing Hansa Biopharma AB (publ)'s (STO:HNSA) CEO Compensation Package
Jun 21Hansa Biopharma AB (publ) (STO:HNSA) Looks Just Right With A 32% Price Jump
May 21Some Analysts Just Cut Their Hansa Biopharma AB (publ) (STO:HNSA) Estimates
Apr 05Analyst Estimates: Here's What Brokers Think Of Hansa Biopharma AB (publ) (STO:HNSA) After Its Yearly Report
Feb 07Hansa Biopharma AB (publ) (STO:HNSA) Not Lagging Industry On Growth Or Pricing
Dec 28Newsflash: Hansa Biopharma AB (publ) (STO:HNSA) Analysts Have Been Trimming Their Revenue Forecasts
Oct 13Does Hansa Biopharma (STO:HNSA) Have A Healthy Balance Sheet?
Sep 22Investors Holding Back On Hansa Biopharma AB (publ) (STO:HNSA)
May 31CEO
Renee Aguiar-Lucander (62 yo)
less than a year
Tenure
Ms. Renee Aguiar-Lucander has been Chief Executive Officer of Hansa Biopharma AB (publ) since April 24, 2025. She serves as Director at Genkyotex SA since November 2020. Ms. Aguiar-Lucander has been Chief...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Executive Officer | less than a year | no data | no data | |
| CFO & Senior VP | 1.2yrs | no data | no data | |
| Vice President of Finance & Administration | 6yrs | no data | no data | |
| VP & Head of Investor Relations | no data | no data | no data | |
| Senior VP & Chief Human Resources Officer | 6.3yrs | no data | 0.021% SEK 370.2k | |
| VP & Head of Business Development | no data | no data | no data | |
| Head of Science | no data | no data | no data | |
| VP & Head of Medical Affairs | no data | no data | no data | |
| VP & Head of Research and Development | 4.1yrs | no data | no data | |
| Senior VP | no data | no data | no data |
4.1yrs
Average Tenure
55yo
Average Age
Experienced Management: HNSA's management team is considered experienced (4.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Independent Director | less than a year | no data | no data | |
| Independent Director | 7yrs | SEK 413.00k | 0.0037% SEK 64.4k | |
| Independent Director | 6yrs | SEK 493.00k | 0.0015% SEK 25.7k | |
| Independent Chairman of the Board | 2.9yrs | SEK 1.14m | 0.036% SEK 630.7k | |
| Independent Director | 6yrs | SEK 591.00k | 0.0044% SEK 77.2k | |
| Independent Director | 4yrs | SEK 725.00k | no data | |
| Chairman of European Medical Advisory Board in Transplantation | no data | no data | no data | |
| Member - European Medical Advisory Board-Transplantation & US Medical Advisory Board-Transplantation | no data | no data | no data | |
| Member of European Medical Advisory Board in Transplantation | no data | no data | no data | |
| Chairman of US Medical Advisory Board in Transplantation | no data | no data | no data | |
| Member of US Medical Advisory Board in Transplantation | no data | no data | no data | |
| Independent Director | less than a year | no data | 0.53% SEK 9.3m |
4.0yrs
Average Tenure
59yo
Average Age
Experienced Board: HNSA's board of directors are considered experienced (4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/07 08:21 |
| End of Day Share Price | 2025/05/07 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Hansa Biopharma AB (publ) is covered by 13 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ABG Sundal Collier |
| Christian Lee | ABG Sundal Collier Sponsored |
| Madhu Kumar | B. Riley Securities, Inc. |